Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization
Case ID:
TAB-2953
Web Published:
12/6/2022
Scientists at the NIH disclosed a mutated adeno-associated virus (AAV) serotype 5 by modifying sialic acid binding regions which mediate viral entry into host cells. Preliminary results from animal studies suggest that this modification can increase transduction by 3-4 folds in salivary glands and muscles, and can significantly decrease the potential of being neutralized by preexisting antibodies compared to the wild type AAV. Thus, the modified AAV5 vectors seem to be optimal for gene therapy. This invention overcomes two major issues in AAV-based gene therapy: the ability to efficiently transduce the target cells and the ability to evade the immune response to vectors.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Modified_AAV5_Vectors_for_En hanced_Transduction_and_Reduced_Antibody_Neutralization
Keywords:
AAV5
ANTIBODY
ENGINEERED
Enhanced
GENETICALLY
Listed LPM Reichman as of 4/15/2015
Neutralization
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
REDUCED
transduction
VAXXXX
VCXXXX
vectors
VFXXXX
VGXXXX
WJXXXX
XEXXXX
YAXXXX
YCXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Vladimir Knezevic
Senior Advisor for Commercial Evaluations
NIH Technology Transfer
301-435-5560
vlado.knezevic@nih.gov